Foresee Pharmaceuticals' linvemastat (FP-020), a novel oral MMP-12 inhibitor, demonstrates a favorable safety and tolerability profile in a Phase 1 clinical trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.